If you have been reading about 研究代号 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
is the half-life, E the total kinetic energy (of the alpha particle and the daughter nucleus), and A and B are coefficients that depend on the isotope's atomic number Z. The law works best for nuclei with even atomic number and even atomic mass. The trend is still there for even-odd, odd-even, and odd-odd nuclei but is not as pronounced.
The Bergmann degradation is a series of chemical reactions designed to remove a single amino acid from the carboxylic acid (C-terminal) end of a peptide. First demonstrated by Max Bergmann in 1934, it is a rarely used method for sequencing peptides. The later developed Edman degradation is an improvement upon the Bergmann degradation, instead cleaving the N-terminal amino acid of peptides to produce a hydantoin containing the desired amino acid. The Bergmann degradation follows the earlier work of Bergmann and his close colleague Leonidas Zervas, combining the organic azide degradation of the Curtius rearrangement with the Bergmann-Zervas carbobenzoxy method, which they designed to occur under relatively mild conditions so as to allow peptide sequencing. A single round of the Bergmann degradation yields an aldehyde containing the sought after amino acid residue and the remaining fragment of the original peptide in amide form.
All nuclear data not otherwise stated is from the standard source: Twenty isotopes of californium are known with mass number ranging from 237 to 256; the most stable are 251Cf with half-life 898 years, 249Cf with half-life 351 years, 250Cf at 13.08 years, and 252Cf at 2.645 years. All other isotopes have half-life shorter than a year, and most of these have half-lives less than 20 minutes. 249Cf is formed by beta decay of berkelium-249, and heavier californium isotopes are made by subjecting berkelium to intense neutron radiation in a nuclear reactor. Though californium-251 has the longest half-life, its production yield is relatively low due to its rapid depletion by reaction with another neutron (high neutron cross section). 252Cf is a very strong neutron emitter, which makes it an extremely hazardous radioactive isotope. 252Cf, 96.9% of the time, alpha decays to curium-248; the other 3.1% of decays are spontaneous fission. One microgram of 252Cf emits 2.3 million neutrons per second (about 3.7 neutrons per fission). The other main isotopes of californium (248-251) also alpha decay to those of curium, with a much smaller fraction of fission.
Sources: en.wikipedia.org
==== TPN-based cholestasis ==== Total parenteral nutrition (TPN) is given to patients with intestinal failure or a variety of other gastrointestinal problems. Under normal settings, TPN causes a slight elevation of ALP levels. However, this does not indicate cholestasis alone. In the case of TPN-induced cholestasis, there is an excessive elevation of ALP, gamma-glutamyltransferase (GGT), and conjugated bilirubin. Without appropriate intervention, symptoms can quickly exacerbate, leading to liver cirrhosis and failure. Cholestasis arising from TPN has a diverse range of causes, including toxicity to TPN components, underlying disorders, or a lack of enteral nutrition. Without enteral food consumption, gallbladder function is greatly inhibited, leading to gallstone formation, subsequent blockage, and eventually cholestasis. Cholestasis resulting from TPN may also be a result of reduced bile flow from portal endotoxins. With TPN, there is a reduction in gastrointestinal motility, immunity, with an increase in permeability. These changes facilitate bacteria growth and increase the amount of circulating endotoxin. Moreover, given that patients using TPN often have underlying health problems, drugs being used with known liver toxicity may also cause cholestasis. Lipids in TPN may cause cholestasis and liver damage by overwhelming clearage mechanisms. Intravenous glucose can also cause cholestasis as a result of increased fatty acid synthesis and decreased breakdown, which facilitates the accumulation of fats.
On the other hand, a similar study (Brachmachari et al.) reported no statistically significant inhibition of the lacZ reporter gene when H-DNA was inserted into the genome of mammalian COS cells. Although studies suggest regulation of H-DNA, the mechanism is still under investigation. Potaman et al. associates the mechanism of gene regulation to the interactions between the H-DNA and the TATA box found in the promoter region of Na,K-ATPase. In H-DNA formations adjacent to a TATA box, the H-DNA structure destabilizes the T-A bonds essential for transcription. The interference with the TATA box inhibits the transcriptional machinery and transcription initiation which interferes with gene expression. Other mechanisms associated with the genomic expression of a genetic sequence in the presence of H-DNA involves TFOs. In vitro studies have highlighted a decrease in gene expression in the presence of TFOs in mammalian cells. Another possible mechanism presented by Valentina et al. suggest the 13-mer AG motif oligonucleotide triplex complex (TFO complex) downregulates the transcription of mRNA through competitive inhibition. Direct inhibition of gene expression from H-DNA is key to mutagenesis, replication inhibition, and even DNA recombination in the genome.
Spiroligomer molecules (also known as bis-peptides) are synthetic oligomers made by coupling pairs of bis-amino acids into a fused ring system. Spiroligomer molecules are rich in stereochemistry and functionality because of the variety of bis-amino acids that are capable of being incorporated during synthesis. Due to the rigidity of the fused ring system, the three-dimensional shape of a Spiroligomer molecule – as well as the display of any functional groups – can be predicted, allowing for molecular modeling and dynamics.
The company's first customers were educational institutions and life-sciences companies that were building supercomputers for purposes of drug discovery, computational fluid dynamics, genetic and genomic research, to predict response to drugs, and for COVID-19 research. Early customers included GlaxoSmithKline, AstraZeneca, the National Energy Technology Laboratory, Lawrence Livermore National Laboratory, the Pittsburgh Supercomputing Center, and Edinburgh Parallel Computing Centre. In September 2020, the company opened an office in Japan and partnered with Tokyo Electron. In April 2021, the company released its CS-2 system, based on the company's Wafer Scale Engine Two (WSE-2), which has 850,000 cores. The CS-2 is manufactured by the 7 nm process of TSMC. It is 26 inches (660 mm) tall and fits in one-third of a standard data center rack. The WSE-2 has 850,000 cores and 2.6 trillion transistors. It enables a single system to support AI models with more than 120 trillion parameters. The WSE-2 expanded on-chip SRAM to 40 gigabytes, memory bandwidth to 20 petabytes per second, and total fabric bandwidth to 220 petabits per second. Customers included TotalEnergies, nference, the National Center for Supercomputing Applications (NCSA), and the Leibniz Supercomputing Centre. In August 2021, Cerebras announced a partnership with Peptilogics on the development of AI for peptide therapeutics. In June 2022, Cerebras set a record for the largest AI models ever trained on one device—a single CS-2 system with one Cerebras wafer trained models with up to 20 billion parameters.
Sources: en.wikipedia.org
In November 1965, when asked to comment by Time after the number of Americans killed in Vietnam passed 1,000, Kissinger praised Johnson for having to make "difficult and lonely decisions". Kissinger compared Johnson to the sheriff played by Gary Cooper in the 1952 film High Noon, depicting Johnson as a heroic figure making necessary, but unpopular decisions. In a 1967 peace initiative, he would mediate between Washington and Hanoi. In June 1967, at an academic conference in Paris, Kissinger met a French biologist, Herbert Marcovitch, who mentioned that one of his friends was Raymond Aubrac, a Communist hero of the French resistance, who in turn was one of the few Westerners who were friends with Ho Chi Minh. Ho had something of an aversion to Westerners and tried to avoid meeting them as much as possible, and Aubrac was unique in being allowed to correspond with Ho. Wanting to play a role in diplomacy, Kissinger contacted the State Department with a plan for Marovitch and Aubrac to go to Hanoi with a peace offer. The Secretary of State, Dean Rusk, was opposed to Kissinger's plan. However, W. Averell Harriman of the "peace shop" was interested and got President Johnson to approve the approach, which was code-named Operation Pennsylvania. In July 1967, Aubrac and Marcovitch went to Hanoi to see Ho, who told him that he was willing to open peace talks with the United States, provided that the Americans "unconditionally" stopped bombing North Vietnam.
=== Small molecule inhibitors === Small molecules that are able to inhibit TGF-β induced EMT are under development. Silmitasertib (CX-4945) is a small molecule inhibitor of protein kinase CK2, which has been supported to be linked with TGF-β induced EMT, and is currently in clinical trials for cholangiocarcinoma (bile duct cancer), as well as in preclinical development for hematological and lymphoid malignancies. In January 2017, Silmitasertib was granted orphan drug status by the U.S. Food and Drug Administration for cholangiocarcinoma and is currently in phase II study. Silmitasertib is being developed by Senhwa Biosciences. Another small molecule inhibitor Galunisertib (LY2157299) is a potent TGF-β type I receptor kinase inhibitor that was demonstrated to reduce the size, the growth rate of tumors, and the tumor forming potential in triple negative breast cancer cell lines using mouse xenografts. Galunisertib is currently being developed by Lilly Oncology and is in phase I/II clinical trials for hepatocellular carcinoma, unresectable pancreatic cancer, and malignant glioma. Small molecule inhibitors of EMT are suggested to not act as a replacement for traditional chemotherapeutic agents but are likely to display the greatest efficacy in treating cancers when used in conjunction with them. Antagomirs and microRNA mimics have gained interest as a potential source of therapeutics to target EMT induced metastasis in cancer as well as treating many other diseases.
It was recommended for parents to safeguard their children by ensuring they have a smoke-free zone. One such way recommended for smokers to protect family, friends, and others is by smoking outside and showering and changing clothes before coming into contact with others. However, research has shown that parents who are heavy smokers (> 10 cigarettes per day) are less likely to believe that third-hand smoke is harmful to children. Third-hand smoke is one of the issues promoting indoor smoking bans, especially supported by performers such as musicians, who are forced to bring third-hand smoke contamination into their homes through contaminated instruments and cases.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。